The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Breast-Cancer Adjuvant Therapy with Zoledronic Acid
Open accessAbstract
BACKGROUND: Data suggest that the adjuvant use of bisphosphonates reduces rates of recurrence and death in patients with early-stage breast cancer. We conducted a study to determine whether treatment with zoledronic acid, in addition to standard adjuvant therapy, would improve disease outcomes in such patients. METHODS: In this open-label phase 3 study, we randomly assigned 3360 patients to receive standard adjuvant systemic therapy either with or without zoledronic acid. The zoledronic acid was administered every 3 to 4 weeks for 6 doses and then every 3 to 6 months to complete 5 years of treatment. The primary end point of the study was disease-free survival. A second interim analysis revealed that a prespecified boundary for lack of benefit had been crossed. RESULTS: At a median follow-up of 59 months, there was no significant between-group difference in the primary end point, with a rate of disease-free survival of 77% in each group (adjusted hazard ratio in the zoledronic acid group, 0.98; 95% confidence interval [CI], 0.85 to 1.13; P=0.79). Disease recurrence or death occurred in 377 patients in the zoledronic acid group and 375 of those in the control group. The numbers of deaths--243 in the zoledronic acid group and 276 in the control group--were also similar, resulting in rates of overall survival of 85.4% in the zoledronic acid group and 83.1% in the control group (adjusted hazard ratio, 0.85; 95% CI, 0.72 to 1.01; P=0.07). In the zoledronic acid group, there were 17 confirmed cases of osteonecrosis of the jaw (cumulative incidence, 1.1%; 95% CI, 0.6 to 1.7; P<0.001) and 9 suspected cases; there were no cases in the control group. Rates of other adverse effects were similar in the two study groups. CONCLUSIONS: These findings do not support the routine use of zoledronic acid in the adjuvant management of breast cancer. (Funded by Novartis Pharmaceuticals and the National Cancer Research Network; AZURE Current Controlled Trials number, ISRCTN79831382.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Marx, R. E. (2003) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/s0278-2391(03)00720-1 · Cited by 3,036
Metastasis to bone: causes, consequences and therapeutic opportunities
Mundy, G. R. (2002) · Nature Reviews Cancer · doi:10.1038/nrc867 · Cited by 2,777
Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
Gnant, M., Mlineritsch, B., Schippinger, W., Luschin-Ebengreuth, G., Pöstlberger, S., Menzel, C., Jakesz, R., Seifert, M., Hubalek, M., Bjelic-Radisic, V., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806285 · Cited by 1,025
Hudis, C. A., Barlow, W. E., Costantino, J. P., Gray, R. J., Pritchard, K. I., Chapman, J.-A. W., Sparano, J. A., Hunsberger, S., Enos, R. A., Gelber, R. D., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.3523 · Cited by 864
Eidtmann, H., de Boer, R., Bundred, N., Llombart-Cussac, A., Davidson, N., Neven, P., von Minckwitz, G., Miller, J., Schenk, N., & Coleman, R. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq217 · Cited by 281
Self-citationAntitumor Effects of Doxorubicin Followed by Zoledronic Acid in a Mouse Model of Breast Cancer
Ottewell, P. D., Monkkonen, H., Jones, M., Lefley, D. V., Coleman, R. E., & Holen, I. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn240 · Cited by 225
Self-citationColeman, R. E., Woodward, E., Brown, J. E., Cameron, D., Bell, R., Dodwell, D. J., Keane, M., Gil, M., Davies, C., Burkinshaw, R., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1429-y · Cited by 120
Self-citationNeville-Webbe, H. L., & Coleman, R. E. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.041 · Cited by 97
Self-citationOttewell, P. D., Deux, B., Mönkkönen, H., Cross, S. S., Coleman, R. E., Clézardin, P., & Holen, I. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1545 · Cited by 90
Self-citation
Cited by
Harbeck, N., & Gnant, M. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31891-8 · Cited by 2,280
Khan, A. A., Morrison, A., Hanley, D. A., Felsenberg, D., McCauley, L. K., O'Ryan, F., Reid, I. R., Ruggiero, S. L., Taguchi, A., Tetradis, S., et al. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2405 · Cited by 1,353
Bulun, S. E., Yilmaz, B. D., Sison, C., Miyazaki, K., Bernardi, L., Liu, S., Kohlmeier, A., Yin, P., Milad, M., & Wei, J. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00242 · Cited by 844
Coleman, R. E., Croucher, P. I., Padhani, A. R., Clézardin, P., Chow, E., Fallon, M., Guise, T., Colangeli, S., Capanna, R., & Costa, L. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00216-3 · Cited by 570
Self-citation
Metadata
- Authors
- Coleman, R. E., Marshall, H., Cameron, D., Dodwell, D., Burkinshaw, R., Keane, M., Gil, M., Houston, S. J., Grieve, R. J., Barrett-Lee, P. J., Ritchie, D., Pugh, J., Gaunt, C., Rea, U., Peterson, J., Davies, C., Hiley, V., Gregory, W., & Bell, R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-10-13
- Volume
- 365
- Issue
- 15
- Pages
- 1396-1405
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2154649532
- Cited by
- 424
- References
- 12
- FWCI
- 26.33
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Breast-Cancer Adjuvant Therapy with Zoledronic Acid. https://app.cochat.ai/papers/10.1056/nejmoa1105195
- The paper
- Coleman, R. E., Marshall, H., Cameron, D., Dodwell, D., Burkinshaw, R., Keane, M., Gil, M., Houston, S. J., Grieve, R. J., Barrett-Lee, P. J., Ritchie, D., Pugh, J., Gaunt, C., Rea, U., Peterson, J., Davies, C., Hiley, V., Gregory, W., & Bell, R. (2011). Breast-Cancer Adjuvant Therapy with Zoledronic Acid. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1105195
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.